CUE-103 / LG Chem, Cue Biopharma - LARVOL DELTA

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November (GlobeNewswire) - "Cue Biopharma, Inc....announced today that it will take part in two fireside chats, the first at the Stifel Healthcare Conference 2021, November 15-17, and the second at the Jefferies London Healthcare Conference, November 16-19...Cue Biopharma will provide an updated corporate overview and recent data highlighting its lead clinical program, CUE-101, representative of the IL-2 based CUE-100 series, as a monotherapy and in combination with KEYRUDA® (pembrolizumab) for the treatment of patients with HPV+ recurrent/metastatic head and neck cancer. The discussion will also focus on the Company’s CUE-100 series pipeline progress with drug product candidates CUE-102, targeting Wilms’ Tumor 1 (WT1) and CUE-103, targeting KRAS G12V, as well as its most recent Neo-STAT™ platform developments."

P1 data • Pipeline update • Head and Neck Cancer • Oncology • Squamous Cell Carcinoma of Head and Neck • Wilms Tumor